Watch Now: Calidi Biotherapeutics and City of Hope announce first patients dosed in a Phase 1 clinical trial
→
Company
Company
About
History
Team
Careers
Medical & Scientific Advisors
Board of Advisors
Our Science
How It Works
Novel Platform
Publications
Medical & Scientific Advisors
Board of Advisors
Our Science
Pipeline
Newsroom
Investors
English
Contact
Publication
First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
The Journal of Translational Medicine
August 19, 2019
A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.
Learn more
A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.
Learn more